Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GE Healthcare has signed a contract to design a new plant-based manufacturing facility in Brazil for Bio-Manguinhos/Fiocruz.
Subscribe to our email newsletter
New facility for Bio-Manguinhos will use iBio’s plant-based protein expression technology, iBioLaunch, and GE Healthcare’s expertise in process design and start-to-finish biopharmaceutical and vaccine manufacturing technologies.
GE Healthcare enterprise solutions general manager Olivier Loeillot said, "GE Healthcare’s global capabilities and industry-leading expertise in biopharmaceutical manufacturing technologies, coupled with iBio’s innovative technology and experience in plant-based protein expression, provide a solid foundation for this design project."
Bio-Manguinhos/Fiocruz acts as a manufacturer of immunobiologicals for public health needs basically supporting Brazilian Ministry of Health programs.
Bio-Manguinhos/Fiocruz director Artur Couto said, "The agreement with GE Healthcare is important because it will allow us to build a new facility based on a very innovative platform and address an important need of the Brazilian Ministry of Health."